Meta-Analysis of Tyrosine Kinase Inhibitor Combination Therapy for Glioblastoma

A meta-analysis synthesizing evidence from 10 randomized controlled trials encompassing 1,435 glioblastoma patients. The dataset, authored by Pan Wei and updated in April 2026, evaluates the efficacy and safety of tyrosine kinase inhibitor combination therapies using progression-free survival, overall survival, and adverse event metrics.

Use Cases

• Assessing the efficacy of combination therapies based on pooled hazard ratios for progression-free survival.
• Evaluating treatment safety profiles based on the reported incidence of specific adverse events like neutropenia and diarrhea.
• Conducting subgroup analyses on treatment regimens or patient status (newly diagnosed vs. recurrent) as described in the results.
• Performing trial sequential analysis to control for false-positive and false-negative conclusions in meta-analyses.

Strengths

• Includes data from 10 randomized controlled trials, a standard for high-quality clinical evidence.
• Reports specific pooled statistical results, including hazard ratios and risk ratios with 95% confidence and prediction intervals.
• Employs trial sequential analysis, a method to enhance the reliability of meta-analytic conclusions.
• Clear focus on a defined clinical question regarding tyrosine kinase inhibitors for glioblastoma.

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment.
• The dataset is very small (18.4 KB), indicating limited raw data scope, likely containing summary statistics rather than patient-level records.
• Freshness should be verified; the last update date is in the future (2026-04-20), which may indicate a placeholder or error.

Provenance

Source

Systematic review of RCTs from PubMed, Cochrane Library, Web of Science, and Embase.

Collection Method

Meta-analysis with trial sequential analysis of identified randomized controlled trials.

Time Range

Trials published up to January 10, 2026.

Freshness

Last updated 2026-04-20 04:11:46; freshness should be verified.

Geography

Global (inferred from inclusion of international trial databases).